300642 Tellgen Corporation
- 14.39
- +0.03+0.21%
Tellgen Corporation News
Tellgen's (SZSE:300642) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Despite Tellgen Corporation's (SZSE:300642) recent earnings report having lackluster headline numbers, the market responded positively. While shareholders may be willing to overlook soft profit numbe
Vision Life (300642.SZ): Net loss of 4.4879 million yuan in the first quarter
On April 22, GLONGHUI (300642.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 93.0721 million yuan, down 23.61% year on year; net profit attributable to shareholders of listed companies was 4.4879 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 5,617,500 yuan; basic earnings per share - 0.0277 yuan.
Institutions Along With Individual Investors Who Hold Considerable Shares InTellgen Corporation (SZSE:300642) Come Under Pressure; Lose 17% of Holdings Value
Key Insights Significant control over Tellgen by individual investors implies that the general public has more power to influence management and governance-related decisions The top 8 shareholders o
Insight Life (300642.SZ) Jiangxi subsidiary obtained 8 medical device registration certificates
Zhitong Finance App News, Taojing Life (300642.SZ) announced that Jiangxi Tuojing Life Technology Co., Ltd. (hereinafter referred to as the “subsidiary” or “Jiangxi Toujing”), a wholly-owned subsidiary of the company, recently obtained 8 medical device registration certificates issued by the Jiangxi Drug Administration.
Vision Life (300642.SZ): Rongzhen Investment plans to reduce its holdings by no more than 1%
Gelonghui, March 14 | Taojing Life (300642.SZ) announced that the company recently received a “Notice Letter on Plans to Reduce the Company's Shares” from the shareholder Shanghai Rongzhen Investment Group Co., Ltd. (“Rongzhen Investment” or “Shareholder”). It plans to reduce the company's shares holdings by no more than 1,637,733 shares through centralized competitive trading or bulk trading on the stock exchange, that is, no more than 1% of the company's current total share capital after excluding the number of shares in the special account for repurchase.
A subsidiary of Toujing Life (300642.SZ) obtained a medical device registration certificate
Toujing Life (300642.SZ) announced that Jiangxi Tuojing Life Technology Co., Ltd., a wholly-owned subsidiary of the company, recently...
Vision Life (300642.SZ): Accumulated investment of 4,555 million yuan to buy back 0.21% of shares
Gelonghui, March 4, 丨 Vision Life (300642.SZ) announced that as of February 29, 2024, the company had repurchased 352,850 shares through a special stock repurchase account, accounting for 0.21% of the company's current total share capital. The highest price for this repurchase of shares was 13.25 yuan/share, the lowest transaction price was 12.36 yuan/share, and the total amount paid was RMB 4,555,125.00.
Insight Life (300642.SZ): Initial repurchase of 135,000 shares involving 1.7078 million yuan
Gelonghui, Feb. 20, 丨 Vision Life (300642.SZ) announced that on February 20, 2024, for the first time, the company repurchased 135,000 shares through a special stock repurchase account, accounting for 0.08% of the company's current total share capital. The highest price for this repurchase of shares was 12.72 yuan/share, the lowest transaction price was 12.36 yuan/share, and the total amount paid was RMB 1.7078 million (not including transaction fees).
The actual controller of Seojing Life (300642.SZ) proposed that the company spend 25 million yuan to 50 million yuan to buy back shares
Insight Life (300642.SZ) issued an announcement. The company recently received the company's actual controller, controlling shareholders, directors...
Vision Life (300642.SZ): Plans to establish a wholly-owned subsidiary in Singapore for 2 million US dollars
On January 4, Greenview Life (300642.SZ) announced that the company plans to establish a wholly-owned subsidiary TELLGEN SINGAPORE PTE in Singapore through foreign direct investment. LTD. (Chinese name: Toujing Life Technology (Singapore) Co., Ltd.) (Tentative name, specific name is based on the final approved name, hereinafter referred to as “Singapore subsidiary”), mainly engaged in R&D, production, sales and technical services of in vitro diagnostic reagents and instruments. The investment amount is 2 million US dollars, and the funding source is its own capital.
Perspective Life (300642.SZ): Currently, the company headquarters and industrialization base are in the construction stage, and the estimated completion time of infrastructure is before June 2025
On December 26, Gelonghui, on the investor interactive platform, some investors asked Perspective Life (300642.SZ), “When is the planned completion time for the new plant? When do you think you'll move in?” The company replied that the company headquarters and industrialization base are currently in the construction stage. The estimated time for completion of the infrastructure is before June 2025, and the later stages will still need to go through hardcover before it can be relocated. The company will pay close attention to the progress of the project and actively promote the construction and implementation of the project.
Toujing Life (300642.SZ), a specific shareholder of Rongzhen Investment, reduced its holdings by a cumulative total of 2.03% at the end of the reduction period
Toujing Life (300642.SZ) announced that the company's specific shareholder Rongzhen Investment's holdings reduction period has expired, and its cumulative holdings have been reduced...
Need To Know: Analysts Just Made A Substantial Cut To Their Tellgen Corporation (SZSE:300642) Estimates
Today is shaping up negative for Tellgen Corporation (SZSE:300642) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. Both revenue and earnings per
Perspective Life (300642.SZ) plans to transfer 3.46% of the shares of the holding subsidiary Pulse Biotech to promote the sustainable and stable development of Pulse Biotech
Teloscopic Life (300642.SZ) announced that the company and its wholly-owned subsidiary Shanghai Teloscopic Diagnostic Technology Co., Ltd. (“Transparent...
Tellgen Corporation (SZSE:300642) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering Tellgen Corporation (SZSE:300642) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenu
Interpretation of Tojing Life's 2023 Interim Report: Net revenue and profit both declined, net cash flow declined, and balance ratio increased slightly
According to Tojing Life's 2023 interim report, the company's revenue was 276,010,359.84 yuan, down 13.92% from 320,628,002.05 yuan in the same period last year. Net profit attributable to shareholders of listed companies was $34,858,945.90, down 19.14% from RMB 43,111,720.79 in the same period last year. This indicates that the company's revenue and net profit both declined during the reporting period. At the same time, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $25,882,668.49, compared to the same period last year
Perspective Life (300642.SZ): Obtained medical device registration certification in Thailand
Glonghui, August 18丨Perspective Life (300642.SZ) announced that some of the company's products have recently obtained registration permits, notices, or filing updates from the Food and Drug Administration of Thailand.
Transparent Life (300642.SZ): Some products have obtained overseas entry qualifications
On July 11, GLONGWI | TOKENG LIFE (300642.SZ) announced that some of the company's products have recently obtained registration permits, notifications or records from the Food and Drug Administration of Thailand (Thailand FDA), as well as EU CE admission. There are a total of 21 items.
It Might Not Be A Great Idea To Buy Tellgen Corporation (SZSE:300642) For Its Next Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tellgen Corporation (SZSE:300642) is about to trade ex-dividend in the next 3 days. The ex-di
0.3% Earnings Growth Over 5 Years Has Not Materialized Into Gains for Tellgen (SZSE:300642) Shareholders Over That Period
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some selections. So we wouldn't blame long term Tellgen Corporation (SZSE:300642) sh
Analysis
Price Target
No Data
